title: Perioperative parenteral tranexamic acid in liver tumor resection: a prospective randomized trial toward a "blood transfusion"-free hepatectomy.
abstract: OBJECTIVE
  To examine the feasibility of a real "blood transfusion"-free hepatectomy in a large group of patients with liver tumors.
  
  
  BACKGROUND
  Bleeding control and blood transfusion remains problematic in liver resection. A real "blood transfusion"-free hepatectomy in a large group of patients has rarely been reported. The impact of tranexamic acid (TA), an antifibrinolytic agent, on blood transfusion in liver resection is unknown.
  
  
  METHODS
  A prospective double-blind randomized trial was performed on elective liver tumor resections. In group A, TA 500 mg was intravenously administered just before operation followed by 250 mg, every 6 hours, for 3 days. In group B, only placebo was given. The patients' background, blood transfusion rates, and early postoperative results in the 2 groups were compared. Factors that influenced blood requirement were analyzed.
  
  
  RESULTS
  There were 108 hepatectomies in group A and 106 hepatectomies in group B. The patients' backgrounds, operative procedures, and hepatectomy extent did not significantly differ between the 2 groups. Although the differences of the operative morbidity and postoperative stay were not significant, a significantly lower amount of operative blood loss, lower blood transfusion rate, shorter operative time, and lower hospital costs were found in group A patients. No patient in group A received blood transfusion. No hospital mortality occurred in either group. Tumor size and use of TA were independent factors that influenced blood transfusion.
  
  
  CONCLUSIONS
  Perioperative parenteral use of TA reduced the amount of operative blood loss and the need for blood transfusion in elective liver tumor resection. A real "blood transfusion"-free hepatectomy may be feasible with the assistance of parenteral TA.
authors.affiliation: Department of Surgery, Taichung Veterans General Hospital, and Department of Surgery, Chung-Shan Medical University, Taichung, Taiwan. he@vghtc.gov.tw
authors.forename: Cheng-Chung
authors.initials: CC
authors.lastname: Wu
authors.forename: Wai-Meng
authors.initials: WM
authors.lastname: Ho
authors.forename: Shao-Bin
authors.initials: SB
authors.lastname: Cheng
authors.forename: Dah-Cherng
authors.initials: DC
authors.lastname: Yeh
authors.forename: Mei-Chin
authors.initials: MC
authors.lastname: Wen
authors.forename: Tse-Jia
authors.initials: TJ
authors.lastname: Liu
authors.forename: Fang-Ku
authors.initials: FK
authors.lastname: P'eng
mesh_terms: D000368:Aged; D000933:Antifibrinolytic Agents / Q000008:administration & dosage*; D016063:Blood Loss, Surgical / Q000517:prevention & control*; D001803:Blood Transfusion / Q000706:statistics & numerical data*; D016009:Chi-Square Distribution; D004311:Double-Blind Method; D005240:Feasibility Studies; D005260:Female; D006498:Hepatectomy / Q000379:methods*; D006801:Humans; D007262:Infusions, Intravenous; D008113:Liver Neoplasms / Q000601:surgery*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D018709:Statistics, Nonparametric; D014148:Tranexamic Acid / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000933:Antifibrinolytic Agents; D014148:Tranexamic Acid